Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CD101 in Healthy Subjects
NCT02551549Phase 1Completed
- Sponsor
- Cidara Therapeutics
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in candidemia and invasive candidiasis comparing CD101 IV with Placebo (2 arms). Primary endpoint: Number of subjects with clinically significant adverse events. Started Sep 2015; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT02551549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551549.